RecruitingPhase 1NCT06135922

Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection

Multicenter, Open Label, Single-arm Exploratory Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection

Sponsor

Chinese PLA General Hospital

Enrollment

9 participants

Start Date

Aug 1, 2023

Study Type

INTERVENTIONAL

Conditions

EBV Infection EBV-associated Hemophagocytic Lymphohistiocytosis

Summary

This is a multi-center, single arm, open-label, phase I study to determine the safety and effectiveness of EBV-TCR-T cell immunotherapy in treating EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH) or EBV infection

Eligibility

Min Age: 1 YearMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called EBV-TCR-T cells for people with ebv infection and ebv-associated hemophagocytic lymphohistiocytosis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 1 Year to 60 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALEBV-TCR-T cells

The patients with EBV-HLH or EBV infection will receive infusions of EBV-TCR-T cells, with the escalated dose ranging from 1×10\^6/kg to 1×10\^8/kg EBV-TCR-T cells per dose.